Light and shadows in the iron chelation treatment of haematological diseases

Area of Science:

• Hematology
• Pharmacology
• Clinical Medicine

Background:

• Iron overload is a significant complication in patients with chronic transfusion-dependent anemias like thalassemia major, sickle-cell disorders, and myelodysplastic syndromes.
• Effective iron chelation therapy is crucial for managing iron toxicity and improving patient outcomes.
• Evaluating the clinical effectiveness and evidence base for different chelator groups is essential for guiding treatment decisions.

Purpose of the Study:

• To review and synthesize the available evidence on the clinical effectiveness of various iron chelator agents.
• To assess the strength of evidence for different chelation treatments based on established guidelines.
• To provide guidance on iron chelation strategies for specific hematological diseases.

Main Methods:

• Systematic review of existing literature on iron chelator groups and their clinical effectiveness.
• Evidence grading according to American College of Cardiology and American Heart Association guidelines.
• Analysis of treatment outcomes in patients with thalassemia major, sickle-cell disorders, and myelodysplastic syndromes.

Main Results:

• Deferoxamine is the primary choice for iron chelation in thalassemia major.
• Deferiprone or deferasirox are alternatives for deferoxamine-intolerant patients or those with high liver iron concentration.
• Continuous subcutaneous or intravenous deferoxamine, or combination therapy, is advised for severe iron overload and heart failure, with emerging support for combined treatments.

Conclusions:

• Deferoxamine remains the gold standard for iron chelation in thalassemia major.
• Treatment decisions should consider patient tolerance, iron levels, and specific disease context.
• Further research is needed to solidify evidence-based conclusions for optimal iron chelation strategies across different hematological conditions.